Form D · Private Equity Fund

OrbiMed Royalty Opportunities II, LP

New York, NY · CIK 0001632107

Offering snapshot reported Feb 2, 2015 · SEC filing

Reported sold
$900M
Offering amount: $900M
Investors reported
83
Form D · investor count
Minimum accepted
$750K
Reported outside-investor minimum
First sale
Jan 30, 2015
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 2, 2015Initial$900,000,000No comparison83SEC filing

Offering details

Securities
Pooled investment fund
Exemptions
06b, 3C, 3C.7
Duration over one year
No
Business combination
No
Sales commissions
$1.5M
Finders' fees
$0
Form D file number
021-233267

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Merrill Lynch, Pierce, Fenner & Smith Incorporated7691

Source: Form D, filed Feb 2, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

ORBIMED ROYALTY OPPORTUNITIES II, LP

Investment adviser: ORBIMED ADVISORS LLC

Gross asset value
$168M
Beneficial owners
272
ADV minimum commitment
$750K

Reported in Form ADV on Feb 25, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator SS&C TECHNOLOGIES, INC. NEW YORK, New York, United States Investor statements: Yes (provided to all investors) Related to adviser: No
Auditor KPMG LLP NEW YORK, New York, United States
Custodian JPMORGAN CHASE BANK, N.A. NEW YORK, New York, United States Related to adviser: No
Custodian SILICON VALLEY BANK NEWTON, Massachusetts, United States Related to adviser: No
Provider details
Annual audit
Yes
Prime brokers
No
Custodians
Yes
Administrator other than the adviser
Yes
External marketing
No

KPMG LLP
PCAOB 185

JPMORGAN CHASE BANK, N.A.
LEI 7H6GLXDRUGQFU57RNE9

Filing source

Form ADV 2049754 · Feb 25, 2026 · Schedule D 7.B.(1), fund 805-1819901255

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Sven H. Borho Executive
Carl L. Gordon Executive
Geoffrey C. Hsu Executive
Samuel D. Isaly Executive
W. Carter Neild Executive
N/A N/A Orbi Med Advisors Llc Executive, Promoter
N/A N/A Orbi Med Rof Ii Llc Executive
Jonathan T. Silverstein Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:
601 Lexington Avenue, 54 Th Floor
New York, NY, 10022